Patent · US Active

Compositions and methods for inhibition of the JAK pathway

US9593082B2 · kind B2 · utility

3Cited by

68References

17Claims

0Family size

Assignee

Rigel Pharmaceuticals, Inc. · US

Inventors

Ankush Argade · Foster City, US
Arvinder Sran · Fremont, US
David Carroll · San Francisco, US
Jeffrey Clough · Redwood City, US
Kin Tso · San Francisco, US
Somasekhar Bhamidipati · Foster City, US
Sambaiah Thota · Fremont, US
Rajinder Singh · Belmont, US
Vanessa Taylor · San Francisco, US
Hui Li · Santa Clara, US
Esteban Masuda · Menlo Park, US

Key dates

Filing date	Feb 12, 2008
Grant date	Mar 14, 2017
Priority date	—
Expiry date	Nov 26, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.